In November 2025, the FDA did something it almost never does: it removed black box warnings -- its most severe safety label -- from hormone replacement therapy products. The warnings for cardiovascular disease, breast cancer, and probable dementia that had defined HRT prescribing for over two decades were stripped from the labels of estrogen and progesterone products used by millions of menopausal women.
The result has been seismic. HRT prescriptions have surged 184% since 2018, with the steepest climb happening after the warning removal. By February 2026, 1 in 20 women aged 45-54 had an active estrogen prescription. Estrogen patch demand jumped so fast it triggered a nationwide shortage that may last through late 2026.
Key Takeaways
- The FDA removed black box warnings for cardiovascular disease, breast cancer, and dementia from menopausal HRT products
- The action was based on updated evidence showing the original 2002 warnings were based on flawed Women's Health Initiative data
- HRT prescriptions have surged 184% since 2018, with the sharpest increase after the warning removal
- Women who start HRT within 10 years of menopause may reduce cardiovascular risk by up to 50%, Alzheimer's risk by 35%, and fracture risk by 50-60%
- Estrogen patch shortages are expected to persist through late 2026 due to demand outpacing manufacturing capacity
What the FDA Actually Changed
On November 7, 2025, HHS announced that the FDA would initiate removal of "misleading" black box warnings from menopausal hormone therapy products. By February 12, 2026, the FDA had approved the first batch of labeling changes for six products across four HRT categories.
Warnings Removed
| Warning Removed |
Original Basis |
Why It Was Removed |
| Cardiovascular disease |
Women's Health Initiative (WHI) 2002 |
WHI enrolled women averaging age 63 -- far past menopause. Women starting HRT within 10 years of menopause show reduced cardiovascular risk |
| Breast cancer |
WHI estrogen + progestin arm |
Absolute risk increase was 8 additional cases per 10,000 women per year. Estrogen-alone arm actually showed decreased breast cancer risk |
| Probable dementia |
WHI Memory Study |
Study enrolled women aged 65-79, not perimenopausal women. Timing hypothesis suggests early HRT may be protective |
Warning That Remains
The endometrial cancer warning for systemic estrogen-alone products was not removed. Women with an intact uterus still need progesterone alongside estrogen to protect the uterine lining. This warning is based on clear, consistent evidence and was never in dispute.
Products Affected
Twenty-nine drug companies have submitted proposed labeling changes. The FDA approved the first six products spanning all four HRT categories: combined estrogen-progesterone, systemic estrogen-alone, systemic progestogen, and topical vaginal estrogen. The remaining products are expected to receive updated labels through 2026.
Why These Warnings Existed in the First Place
The black box warnings trace back to a single moment: July 9, 2002, when the Women's Health Initiative (WHI) halted its estrogen-plus-progestin trial early due to what appeared to be increased risks of heart disease and breast cancer.
The media response was immediate and devastating. Headlines screamed that HRT caused heart attacks and cancer. Within months, HRT prescriptions dropped by 50%. Millions of women stopped therapy or never started it.
What the WHI Actually Found
The problem wasn't the trial itself -- it was how the results were interpreted and communicated.
The age problem. The average WHI participant was 63 years old -- over a decade past menopause. Most had never used HRT before. Applying these results to women in their late 40s and early 50s starting HRT at menopause onset was, as the FDA now acknowledges, misleading.
The timing hypothesis. Subsequent analysis of WHI data and other studies revealed a critical pattern: women who started HRT within 10 years of menopause had fundamentally different outcomes than those who started later. Early initiators showed reduced cardiovascular risk, while late initiators showed increased risk.
The absolute risk. The WHI's own numbers showed an absolute increase of 8 additional breast cancer cases per 10,000 women per year in the combined hormone arm. The estrogen-alone arm (for women without a uterus) actually showed a decrease in breast cancer -- a finding largely ignored in media coverage.
The benefits ignored. The WHI also showed significant reductions in hip fractures, colorectal cancer, and total mortality in certain subgroups. These benefits were buried under the cancer and heart disease headlines.
The Evidence That Changed the FDA's Mind
The FDA's reversal wasn't impulsive. It followed two decades of accumulating evidence that contradicted the original WHI interpretation.
Mortality and Cardiovascular Data
Randomized studies now show that women who initiate HRT within 10 years of menopause onset have:
- Up to 50% reduction in cardiovascular disease risk
- 35% reduction in Alzheimer's disease risk
- 50-60% reduction in bone fracture risk
- Reduction in all-cause mortality
A 2026 study presented at the American Academy of Orthopaedic Surgeons (AAOS) annual meeting found that early HRT reduces the risk of osteoporotic fractures in postmenopausal women by 13%, adding to the growing body of evidence for skeletal benefits.
The Timing Window
The concept of a "window of opportunity" has become central to modern HRT prescribing. Starting HRT within 10 years of menopause -- generally before age 60 -- produces different biological effects than starting it a decade or more later.
In younger, healthier blood vessels, estrogen maintains protective effects on endothelial function, lipid profiles, and inflammation. In older vessels already affected by atherosclerosis, the same hormone may destabilize existing plaques. This explains why the WHI (which enrolled older women) and studies of younger women reached opposite conclusions.
Professional Society Consensus
The Endocrine Society, the North American Menopause Society, and the American College of Obstetricians and Gynecologists all support HRT for symptomatic menopausal women within the timing window. The FDA's label changes now align with what these organizations have recommended for years.
The Prescription Surge -- By the Numbers
The warning removal triggered the fastest growth in HRT prescribing in two decades.
Truveta Data (Real-World Prescriptions)
| Metric |
Finding |
| Overall HRT growth |
184% increase in estrogen-based HRT among women 45-54 since 2018 |
| Patch demand |
26% jump in estrogen patch use by February 2026 (post-warning removal) |
| Current prevalence |
1 in 20 women aged 45-54 now has an active estrogen HRT prescription |
| Fastest-growing forms |
Transdermal patches and vaginal creams |
The Supply Problem
This surge created an unintended crisis. The US has only a handful of estrogen patch manufacturers, and demand growth of this magnitude overwhelmed existing supply chains. Nearly every major patch brand -- Dotti, Lyllana, Vivelle-Dot, Climara, Minivelle -- is on backorder. AbbVie discontinued Alora entirely.
The shortage is expected to persist through late 2026 or longer. If you're affected, read our guide on estrogen patch shortage alternatives for practical options.
What This Means for You
If You're Considering HRT for the First Time
The warning removal lowers one barrier -- stigma and fear driven by outdated labels -- but doesn't change the medical decision itself. HRT is appropriate if you have menopausal symptoms and fall within the timing window (within 10 years of menopause, generally under 60).
Steps to take:
- Get baseline labs. Estradiol, FSH, testosterone, thyroid panel, and a lipid panel give your provider a clear starting point. Our guide on how to test testosterone covers the process.
- Find a specialist. Not every primary care doctor is comfortable prescribing HRT. Online clinics that specialize in women's hormone therapy can provide expert guidance. See our best online HRT clinics for women.
- Discuss formulation options. Transdermal estradiol (patch, gel, cream) is generally preferred over oral for lower clot risk. Add progesterone if you have a uterus. Consider testosterone if libido, energy, or cognitive symptoms persist.
- Plan for the patch shortage. If your provider recommends patches, have a backup plan. Estradiol gel and cream deliver the same hormone through the same transdermal route.
If You're Already on HRT
The label changes validate what your provider likely already knew -- the benefits outweigh the risks for most symptomatic menopausal women who start within the timing window. No changes to your current regimen are needed based on the warning removal alone.
If You Stopped HRT After 2002
Many women discontinued HRT in response to the original WHI scare. If you stopped and symptoms returned -- or if you've since developed osteoporosis, cardiovascular risk factors, or cognitive changes -- it may be worth revisiting HRT with your provider. The evidence landscape has changed dramatically.
The Bigger Picture
The HRT black box warning removal is part of a broader regulatory shift in hormone therapy. In parallel, an FDA expert panel recommended descheduling testosterone and expanding its indications. The pattern is clear: decades of overly cautious regulation based on flawed or misinterpreted data are being corrected as better evidence accumulates.
For women, this means access to HRT is expanding at every level -- fewer label barriers, more telehealth options, growing provider comfort, and a medical establishment that finally acknowledges what the data has shown for years: for most symptomatic women who start within the timing window, hormone replacement therapy does more good than harm.
References
- HHS. "HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy." FDA.gov. November 2025.
- FDA. "FDA Approves Labeling Changes to Menopausal Hormone Therapy Products." FDA.gov. February 2026.
- Truveta. "Estrogen HRT use is rising: Real-world trends." Truveta.com. 2026.
- AAOS 2026 Annual Meeting. "New study finds early hormone replacement therapy reduces risk of osteoporosis and fractures for older women." 2026.
- Rossouw JE, et al. "Risks and benefits of estrogen plus progestin in healthy postmenopausal women." JAMA. 2002;288(3):321-333.
- Manson JE, et al. "Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality." JAMA. 2017;318(10):927-938.